Bestore vs CSPC Innovation Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Bestore Co Ltd (603719.CG)

Q3 202613 Jul – 24 Aug 2026

▲2▼2

Bestore swings to profit as turnaround takes hold, but big shareholders keep selling

First-half profit confirms turnaround Bestore reported a first-half net profit of 16.19 million yuan, reversing a loss, with revenue up 11.18% to 3.145 billion yuan. The company says product mix, channel efficiency and supply-chain upgrades are working. This is the clearest sign yet that the business is recovering, which supports the share price.
It is the period's biggest positive fundamental event and directly answers what is driving the stock.
Early profit forecast set the stage In mid-July, Bestore guided that it would swing to a first-half profit of 16–24 million yuan, versus a loss a year earlier, thanks to higher revenue and gross margin. The forecast primed investors for the recovery that the later results confirmed.
It is the first concrete signal of the profit turnaround and explains the positive shift in sentiment.
Major shareholders keep selling Two large shareholders cut their stakes in July: Dayong Limited sold 8.73 million shares, and Davy Limited sold 11.94 million shares for 103 million yuan. Continued selling by big owners can pressure the share price and makes some investors question their confidence in the company.
It is the main negative force this period and a real counterweight to the improving earnings.
Weak cash returns and slow new-store rollout Bestore said interest income fell 80% because deposit rates dropped, and its 934 million yuan of wealth-management products produced no disposal gains. Its new Fresh Life supermarket format still has only one pilot store. Both point to weak cash returns and slow expansion beyond the core snack business.
It highlights financial and growth weaknesses that could limit the recovery story.

August 202613 Jul – 24 Aug 2026

▲2▼2

Bestore swings to profit as turnaround takes hold, but big shareholders keep selling

First-half profit confirms turnaround Bestore reported a first-half net profit of 16.19 million yuan, reversing a loss, with revenue up 11.18% to 3.145 billion yuan. The company says product mix, channel efficiency and supply-chain upgrades are working. This is the clearest sign yet that the business is recovering, which supports the share price.
It is the period's biggest positive fundamental event and directly answers what is driving the stock.
Early profit forecast set the stage In mid-July, Bestore guided that it would swing to a first-half profit of 16–24 million yuan, versus a loss a year earlier, thanks to higher revenue and gross margin. The forecast primed investors for the recovery that the later results confirmed.
It is the first concrete signal of the profit turnaround and explains the positive shift in sentiment.
Major shareholders keep selling Two large shareholders cut their stakes in July: Dayong Limited sold 8.73 million shares, and Davy Limited sold 11.94 million shares for 103 million yuan. Continued selling by big owners can pressure the share price and makes some investors question their confidence in the company.
It is the main negative force this period and a real counterweight to the improving earnings.
Weak cash returns and slow new-store rollout Bestore said interest income fell 80% because deposit rates dropped, and its 934 million yuan of wealth-management products produced no disposal gains. Its new Fresh Life supermarket format still has only one pilot store. Both point to weak cash returns and slow expansion beyond the core snack business.
It highlights financial and growth weaknesses that could limit the recovery story.

Latest13 Jul – 24 Aug 2026

▲2▼2

Bestore swings to profit as turnaround takes hold, but big shareholders keep selling

First-half profit confirms turnaround Bestore reported a first-half net profit of 16.19 million yuan, reversing a loss, with revenue up 11.18% to 3.145 billion yuan. The company says product mix, channel efficiency and supply-chain upgrades are working. This is the clearest sign yet that the business is recovering, which supports the share price.
It is the period's biggest positive fundamental event and directly answers what is driving the stock.
Early profit forecast set the stage In mid-July, Bestore guided that it would swing to a first-half profit of 16–24 million yuan, versus a loss a year earlier, thanks to higher revenue and gross margin. The forecast primed investors for the recovery that the later results confirmed.
It is the first concrete signal of the profit turnaround and explains the positive shift in sentiment.
Major shareholders keep selling Two large shareholders cut their stakes in July: Dayong Limited sold 8.73 million shares, and Davy Limited sold 11.94 million shares for 103 million yuan. Continued selling by big owners can pressure the share price and makes some investors question their confidence in the company.
It is the main negative force this period and a real counterweight to the improving earnings.
Weak cash returns and slow new-store rollout Bestore said interest income fell 80% because deposit rates dropped, and its 934 million yuan of wealth-management products produced no disposal gains. Its new Fresh Life supermarket format still has only one pilot store. Both point to weak cash returns and slow expansion beyond the core snack business.
It highlights financial and growth weaknesses that could limit the recovery story.

CSPC Innovation Pharmaceutical Co Ltd Class A (300765.CS)

Q3 202616 Jul – 14 Sep 2026

▲3

CSPC Innovation Swings to Profit as Cancer Drug Pipeline Hits Key Milestones

Interim profit turnaround confirms commercial ramp CSPC Innovation reported a first-half net profit of 1.261 billion yuan, reversing a year-ago loss, with revenue up 208.7% to 3.24 billion yuan and a 76.7% gross margin. This shows the biopharma business is now generating real cash and earnings, which supports the stock's valuation.
The swing to profit is the clearest fundamental driver of the stock's value and confirms the business is no longer loss-making.
SYS6010 Phase III success and strong lung cancer data SYS6010 met its main goal in a Phase III lung cancer trial, and new data showed it combined with another drug shrank tumors in up to 82.4% of high-PD-L1 patients. These results raise the odds of approval and future sales, boosting investor confidence.
This is the most advanced pipeline asset with late-stage success, directly increasing the probability of a major new revenue stream.
Two new drug applications advance toward market A marketing application for a HER2 ADC for breast cancer was accepted, and a Phase III trial for a B7-H3 ADC in ovarian cancer began. Both move the company closer to adding new approved products, which would broaden future revenue.
These regulatory and clinical steps expand the pipeline and signal more near-term product launches.

August 202616 Jul – 14 Sep 2026

▲3

CSPC Innovation Swings to Profit as Cancer Drug Pipeline Hits Key Milestones

Interim profit turnaround confirms commercial ramp CSPC Innovation reported a first-half net profit of 1.261 billion yuan, reversing a year-ago loss, with revenue up 208.7% to 3.24 billion yuan and a 76.7% gross margin. This shows the biopharma business is now generating real cash and earnings, which supports the stock's valuation.
The swing to profit is the clearest fundamental driver of the stock's value and confirms the business is no longer loss-making.
SYS6010 Phase III success and strong lung cancer data SYS6010 met its main goal in a Phase III lung cancer trial, and new data showed it combined with another drug shrank tumors in up to 82.4% of high-PD-L1 patients. These results raise the odds of approval and future sales, boosting investor confidence.
This is the most advanced pipeline asset with late-stage success, directly increasing the probability of a major new revenue stream.
Two new drug applications advance toward market A marketing application for a HER2 ADC for breast cancer was accepted, and a Phase III trial for a B7-H3 ADC in ovarian cancer began. Both move the company closer to adding new approved products, which would broaden future revenue.
These regulatory and clinical steps expand the pipeline and signal more near-term product launches.

Latest16 Jul – 14 Sep 2026

▲3

CSPC Innovation Swings to Profit as Cancer Drug Pipeline Hits Key Milestones

Interim profit turnaround confirms commercial ramp CSPC Innovation reported a first-half net profit of 1.261 billion yuan, reversing a year-ago loss, with revenue up 208.7% to 3.24 billion yuan and a 76.7% gross margin. This shows the biopharma business is now generating real cash and earnings, which supports the stock's valuation.
The swing to profit is the clearest fundamental driver of the stock's value and confirms the business is no longer loss-making.
SYS6010 Phase III success and strong lung cancer data SYS6010 met its main goal in a Phase III lung cancer trial, and new data showed it combined with another drug shrank tumors in up to 82.4% of high-PD-L1 patients. These results raise the odds of approval and future sales, boosting investor confidence.
This is the most advanced pipeline asset with late-stage success, directly increasing the probability of a major new revenue stream.
Two new drug applications advance toward market A marketing application for a HER2 ADC for breast cancer was accepted, and a Phase III trial for a B7-H3 ADC in ovarian cancer began. Both move the company closer to adding new approved products, which would broaden future revenue.
These regulatory and clinical steps expand the pipeline and signal more near-term product launches.